| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Amyloidosis | 123 | 2024 | 808 | 17.700 |
Why?
|
| Amyloid Neuropathies, Familial | 25 | 2023 | 140 | 8.580 |
Why?
|
| Cardiomyopathies | 75 | 2024 | 1924 | 8.160 |
Why?
|
| Prealbumin | 39 | 2023 | 215 | 6.570 |
Why?
|
| Immunoglobulin Light Chains | 17 | 2024 | 277 | 2.530 |
Why?
|
| Benzoxazoles | 5 | 2022 | 88 | 1.990 |
Why?
|
| Electric Countershock | 13 | 2024 | 536 | 1.850 |
Why?
|
| Anti-Arrhythmia Agents | 17 | 2012 | 781 | 1.810 |
Why?
|
| Heart Diseases | 20 | 2020 | 2790 | 1.710 |
Why?
|
| Atrial Fibrillation | 41 | 2024 | 5148 | 1.640 |
Why?
|
| Myocardium | 31 | 2022 | 4652 | 1.430 |
Why?
|
| Radionuclide Imaging | 14 | 2022 | 1978 | 1.420 |
Why?
|
| Heart Failure | 31 | 2024 | 11729 | 1.390 |
Why?
|
| Ethylene Glycols | 8 | 2024 | 190 | 1.370 |
Why?
|
| Echocardiography | 35 | 2022 | 4950 | 1.350 |
Why?
|
| Amyloid | 18 | 2023 | 825 | 1.280 |
Why?
|
| Ventricular Function, Left | 13 | 2024 | 3830 | 1.120 |
Why?
|
| Aniline Compounds | 8 | 2024 | 1056 | 1.020 |
Why?
|
| Technetium | 9 | 2022 | 320 | 0.920 |
Why?
|
| Heart | 14 | 2022 | 4377 | 0.850 |
Why?
|
| Electrocardiography | 34 | 2019 | 6380 | 0.840 |
Why?
|
| Echocardiography, Doppler | 12 | 2020 | 900 | 0.830 |
Why?
|
| Serum Amyloid P-Component | 1 | 2022 | 46 | 0.800 |
Why?
|
| Atrial Function, Left | 4 | 2017 | 184 | 0.790 |
Why?
|
| Carboxylic Acids | 1 | 2022 | 92 | 0.780 |
Why?
|
| Digoxin | 10 | 2002 | 247 | 0.720 |
Why?
|
| Amiodarone | 3 | 2012 | 218 | 0.710 |
Why?
|
| Pyrrolidines | 1 | 2022 | 335 | 0.700 |
Why?
|
| Echocardiography, Doppler, Pulsed | 3 | 2005 | 69 | 0.680 |
Why?
|
| Atrial Flutter | 7 | 2003 | 258 | 0.680 |
Why?
|
| Melphalan | 13 | 2011 | 418 | 0.660 |
Why?
|
| Cardiomyopathy, Hypertrophic | 2 | 2022 | 1264 | 0.650 |
Why?
|
| Myeloma Proteins | 2 | 2019 | 71 | 0.620 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2024 | 1109 | 0.610 |
Why?
|
| Cardiomyopathy, Restrictive | 4 | 2015 | 62 | 0.600 |
Why?
|
| Humans | 240 | 2024 | 752411 | 0.590 |
Why?
|
| Myocardial Contraction | 7 | 2010 | 1512 | 0.590 |
Why?
|
| Diphosphates | 7 | 2022 | 84 | 0.580 |
Why?
|
| Predictive Value of Tests | 24 | 2024 | 15143 | 0.540 |
Why?
|
| Tachycardia | 7 | 2000 | 603 | 0.520 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 1 | 2017 | 179 | 0.510 |
Why?
|
| Phenethylamines | 3 | 2000 | 95 | 0.500 |
Why?
|
| Ventricular Fibrillation | 3 | 2008 | 537 | 0.500 |
Why?
|
| Positron-Emission Tomography | 5 | 2022 | 6413 | 0.500 |
Why?
|
| Cardiac Pacing, Artificial | 10 | 1995 | 859 | 0.480 |
Why?
|
| Echocardiography, Doppler, Color | 3 | 2015 | 353 | 0.470 |
Why?
|
| Tendon Injuries | 1 | 2017 | 325 | 0.460 |
Why?
|
| Disopyramide | 2 | 2012 | 15 | 0.460 |
Why?
|
| Bone Marrow Examination | 1 | 2013 | 156 | 0.450 |
Why?
|
| Magnetic Resonance Imaging | 9 | 2022 | 35932 | 0.440 |
Why?
|
| Aged | 84 | 2024 | 166585 | 0.440 |
Why?
|
| Systole | 8 | 2018 | 948 | 0.430 |
Why?
|
| Blood Flow Velocity | 6 | 2014 | 1369 | 0.430 |
Why?
|
| Gadolinium DTPA | 2 | 2015 | 825 | 0.420 |
Why?
|
| Atrial Function | 4 | 2015 | 99 | 0.410 |
Why?
|
| Anticoagulants | 7 | 2007 | 4831 | 0.410 |
Why?
|
| Heart Rate | 15 | 2006 | 4092 | 0.400 |
Why?
|
| Male | 120 | 2024 | 354908 | 0.400 |
Why?
|
| Posture | 2 | 2014 | 952 | 0.380 |
Why?
|
| Immunoglobulin kappa-Chains | 3 | 2020 | 170 | 0.380 |
Why?
|
| Magnetic Resonance Imaging, Cine | 7 | 2021 | 1015 | 0.380 |
Why?
|
| Middle Aged | 102 | 2024 | 217039 | 0.370 |
Why?
|
| Female | 110 | 2024 | 386085 | 0.370 |
Why?
|
| Calcium Channel Blockers | 4 | 2011 | 690 | 0.360 |
Why?
|
| Radiopharmaceuticals | 7 | 2024 | 2652 | 0.360 |
Why?
|
| Myxoma | 1 | 2011 | 115 | 0.360 |
Why?
|
| Technetium Tc 99m Pyrophosphate | 7 | 2022 | 39 | 0.360 |
Why?
|
| Cardiology | 5 | 2020 | 1704 | 0.350 |
Why?
|
| Potassium Channel Blockers | 2 | 2000 | 162 | 0.350 |
Why?
|
| Microvessels | 1 | 2014 | 571 | 0.350 |
Why?
|
| Stroke Volume | 12 | 2022 | 5451 | 0.340 |
Why?
|
| Heart Failure, Systolic | 1 | 2011 | 135 | 0.330 |
Why?
|
| Cardiomyopathy, Dilated | 5 | 2004 | 818 | 0.330 |
Why?
|
| Dyspnea | 3 | 2014 | 1346 | 0.330 |
Why?
|
| Warfarin | 9 | 2004 | 1506 | 0.330 |
Why?
|
| Paraproteinemias | 4 | 2020 | 246 | 0.320 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2018 | 1066 | 0.320 |
Why?
|
| Patient Education as Topic | 1 | 2018 | 2294 | 0.310 |
Why?
|
| Military Personnel | 1 | 2017 | 1143 | 0.310 |
Why?
|
| Heart Conduction System | 5 | 2000 | 1014 | 0.310 |
Why?
|
| Colchicine | 4 | 2024 | 257 | 0.310 |
Why?
|
| Verapamil | 4 | 2002 | 242 | 0.310 |
Why?
|
| Antibodies, Monoclonal | 3 | 2022 | 9101 | 0.300 |
Why?
|
| Aortic Valve Stenosis | 1 | 2020 | 2067 | 0.290 |
Why?
|
| Heart Atria | 7 | 2021 | 1340 | 0.290 |
Why?
|
| Heart Neoplasms | 1 | 2011 | 362 | 0.290 |
Why?
|
| Prognosis | 25 | 2024 | 29337 | 0.290 |
Why?
|
| Natriuretic Peptide, Brain | 3 | 2024 | 1692 | 0.290 |
Why?
|
| Mitral Valve Stenosis | 2 | 2004 | 341 | 0.290 |
Why?
|
| Wolff-Parkinson-White Syndrome | 2 | 2000 | 116 | 0.280 |
Why?
|
| Ventricular Dysfunction, Left | 6 | 2014 | 2122 | 0.280 |
Why?
|
| Hypercalcemia | 1 | 2009 | 415 | 0.280 |
Why?
|
| Fluorine Radioisotopes | 2 | 2020 | 448 | 0.270 |
Why?
|
| Pacemaker, Artificial | 5 | 2001 | 812 | 0.270 |
Why?
|
| Diagnosis, Differential | 12 | 2016 | 12901 | 0.260 |
Why?
|
| Tachycardia, Ventricular | 3 | 2008 | 1292 | 0.260 |
Why?
|
| Sulfonamides | 3 | 2000 | 1963 | 0.250 |
Why?
|
| Amyloidosis, Familial | 2 | 2002 | 16 | 0.250 |
Why?
|
| Biopsy | 11 | 2021 | 6743 | 0.250 |
Why?
|
| Contrast Media | 4 | 2021 | 5285 | 0.250 |
Why?
|
| Drug Therapy, Combination | 8 | 2022 | 6479 | 0.250 |
Why?
|
| Acenocoumarol | 1 | 2004 | 19 | 0.250 |
Why?
|
| Arrhythmias, Cardiac | 8 | 2005 | 2243 | 0.250 |
Why?
|
| Multiple Myeloma | 2 | 2013 | 5110 | 0.240 |
Why?
|
| American Heart Association | 2 | 2019 | 1070 | 0.240 |
Why?
|
| Catheter Ablation | 4 | 2015 | 2724 | 0.240 |
Why?
|
| Aged, 80 and over | 23 | 2023 | 58299 | 0.240 |
Why?
|
| Salicylates | 1 | 2004 | 125 | 0.240 |
Why?
|
| Sarcoidosis | 1 | 2010 | 515 | 0.230 |
Why?
|
| Familial Mediterranean Fever | 1 | 2024 | 65 | 0.230 |
Why?
|
| Diastole | 5 | 2014 | 788 | 0.230 |
Why?
|
| Hypertrophy, Left Ventricular | 3 | 2014 | 853 | 0.220 |
Why?
|
| Mutation | 10 | 2020 | 29706 | 0.220 |
Why?
|
| Protein Folding | 2 | 2018 | 843 | 0.220 |
Why?
|
| Automobile Driving | 1 | 2008 | 434 | 0.220 |
Why?
|
| Prevalence | 10 | 2020 | 15508 | 0.220 |
Why?
|
| Immunoglobulin lambda-Chains | 2 | 2017 | 82 | 0.210 |
Why?
|
| Sotalol | 3 | 2003 | 47 | 0.210 |
Why?
|
| Coronary Vessels | 1 | 2014 | 3107 | 0.210 |
Why?
|
| Flecainide | 2 | 1994 | 41 | 0.200 |
Why?
|
| Diagnostic Imaging | 3 | 2011 | 3502 | 0.200 |
Why?
|
| Cardiac Imaging Techniques | 2 | 2021 | 275 | 0.200 |
Why?
|
| Plasma Cells | 2 | 2017 | 588 | 0.190 |
Why?
|
| Heart Transplantation | 5 | 2024 | 3061 | 0.190 |
Why?
|
| Intracranial Hemorrhages | 1 | 2007 | 843 | 0.190 |
Why?
|
| Tellurium | 1 | 2020 | 21 | 0.190 |
Why?
|
| Cardiac-Gated Single-Photon Emission Computer-Assisted Tomography | 1 | 2020 | 4 | 0.180 |
Why?
|
| Defibrillators, Implantable | 2 | 2008 | 1481 | 0.180 |
Why?
|
| Heart Auscultation | 1 | 2000 | 34 | 0.180 |
Why?
|
| Adrenergic beta-Antagonists | 4 | 2011 | 1247 | 0.180 |
Why?
|
| Coitus | 1 | 2001 | 131 | 0.180 |
Why?
|
| Pleural Effusion | 1 | 2003 | 336 | 0.180 |
Why?
|
| RNA, Small Interfering | 2 | 2020 | 3447 | 0.180 |
Why?
|
| Early Diagnosis | 3 | 2020 | 1178 | 0.180 |
Why?
|
| Amyloidogenic Proteins | 2 | 2023 | 150 | 0.170 |
Why?
|
| Amino Acid Substitution | 3 | 2020 | 1734 | 0.170 |
Why?
|
| Heart Ventricles | 11 | 2024 | 3805 | 0.170 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2001 | 239 | 0.170 |
Why?
|
| Ultrasonography | 9 | 2015 | 5919 | 0.170 |
Why?
|
| Cadmium | 1 | 2020 | 215 | 0.170 |
Why?
|
| Placebos | 3 | 2019 | 1665 | 0.160 |
Why?
|
| Stem Cell Transplantation | 4 | 2011 | 1600 | 0.160 |
Why?
|
| Societies, Medical | 3 | 2020 | 3834 | 0.160 |
Why?
|
| Signal Processing, Computer-Assisted | 2 | 1997 | 1478 | 0.160 |
Why?
|
| Sinoatrial Node | 2 | 1995 | 98 | 0.160 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2024 | 616 | 0.160 |
Why?
|
| Electrodes | 2 | 1993 | 609 | 0.160 |
Why?
|
| Gadolinium | 2 | 2018 | 948 | 0.160 |
Why?
|
| Pulmonary Veins | 3 | 2011 | 732 | 0.150 |
Why?
|
| Time Factors | 10 | 2024 | 39846 | 0.150 |
Why?
|
| Disease Progression | 9 | 2020 | 13405 | 0.150 |
Why?
|
| Adenosine | 1 | 2003 | 825 | 0.150 |
Why?
|
| Tachycardia, Supraventricular | 3 | 2015 | 272 | 0.150 |
Why?
|
| Treatment Outcome | 19 | 2022 | 64250 | 0.150 |
Why?
|
| Hospitalization | 6 | 2019 | 10629 | 0.150 |
Why?
|
| Coronary Circulation | 3 | 2014 | 1565 | 0.150 |
Why?
|
| Benzoates | 1 | 2019 | 212 | 0.150 |
Why?
|
| Rupture, Spontaneous | 1 | 2017 | 352 | 0.140 |
Why?
|
| Radioactive Tracers | 2 | 2020 | 67 | 0.140 |
Why?
|
| Risk Factors | 14 | 2024 | 73425 | 0.130 |
Why?
|
| Antineoplastic Agents, Alkylating | 5 | 2004 | 617 | 0.130 |
Why?
|
| Platelet Aggregation Inhibitors | 3 | 2004 | 3160 | 0.130 |
Why?
|
| Zinc | 1 | 2020 | 688 | 0.130 |
Why?
|
| Drug Administration Schedule | 4 | 2015 | 4876 | 0.130 |
Why?
|
| Heart Function Tests | 2 | 2010 | 318 | 0.130 |
Why?
|
| Pulse | 1 | 1996 | 218 | 0.130 |
Why?
|
| Survival Analysis | 11 | 2019 | 10172 | 0.130 |
Why?
|
| Immunosuppressive Agents | 4 | 2010 | 4067 | 0.130 |
Why?
|
| Adult | 52 | 2020 | 216927 | 0.130 |
Why?
|
| Genotype | 3 | 2020 | 12869 | 0.130 |
Why?
|
| Stroke | 4 | 2007 | 9879 | 0.130 |
Why?
|
| Cerebrovascular Disorders | 5 | 1998 | 1492 | 0.130 |
Why?
|
| Thyrotoxicosis | 1 | 1995 | 83 | 0.120 |
Why?
|
| Syncope | 1 | 1997 | 423 | 0.120 |
Why?
|
| Decision Trees | 1 | 2016 | 504 | 0.120 |
Why?
|
| Esophageal Achalasia | 1 | 1995 | 95 | 0.120 |
Why?
|
| Arm | 1 | 2017 | 582 | 0.120 |
Why?
|
| Ventricular Remodeling | 1 | 2022 | 1244 | 0.120 |
Why?
|
| Cardiac Output | 1 | 1997 | 832 | 0.120 |
Why?
|
| International Normalized Ratio | 2 | 2007 | 379 | 0.120 |
Why?
|
| Diuretics | 2 | 2011 | 611 | 0.120 |
Why?
|
| Protein Structure, Quaternary | 1 | 2015 | 427 | 0.110 |
Why?
|
| Consensus | 5 | 2021 | 3034 | 0.110 |
Why?
|
| Disease Management | 2 | 2020 | 2480 | 0.110 |
Why?
|
| Case-Control Studies | 5 | 2019 | 21851 | 0.110 |
Why?
|
| Vasomotor System | 1 | 2014 | 207 | 0.110 |
Why?
|
| Lupus Nephritis | 1 | 1997 | 309 | 0.110 |
Why?
|
| Women's Health | 1 | 2023 | 2047 | 0.110 |
Why?
|
| Mass Spectrometry | 3 | 2018 | 2176 | 0.110 |
Why?
|
| Thromboembolism | 3 | 1998 | 997 | 0.110 |
Why?
|
| Peptide Fragments | 2 | 2024 | 5070 | 0.110 |
Why?
|
| Marfan Syndrome | 1 | 1995 | 231 | 0.110 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 1768 | 0.110 |
Why?
|
| Death, Sudden, Cardiac | 4 | 2010 | 1561 | 0.110 |
Why?
|
| Cardiotoxins | 1 | 2013 | 37 | 0.110 |
Why?
|
| Physical Exertion | 2 | 1996 | 660 | 0.110 |
Why?
|
| United States | 13 | 2022 | 71438 | 0.110 |
Why?
|
| Electrocardiography, Ambulatory | 4 | 1998 | 578 | 0.110 |
Why?
|
| Protein Stability | 1 | 2015 | 565 | 0.110 |
Why?
|
| Magnesium | 1 | 1996 | 807 | 0.110 |
Why?
|
| Survival Rate | 8 | 2005 | 12745 | 0.110 |
Why?
|
| Immunoglobulin M | 1 | 2018 | 1519 | 0.110 |
Why?
|
| Hyperemia | 1 | 2014 | 221 | 0.110 |
Why?
|
| Reproducibility of Results | 5 | 2020 | 19901 | 0.110 |
Why?
|
| Electrophysiology | 3 | 2001 | 1264 | 0.100 |
Why?
|
| Clinical Trials as Topic | 8 | 2012 | 7996 | 0.100 |
Why?
|
| Thalidomide | 2 | 2011 | 883 | 0.100 |
Why?
|
| Biopsy, Needle | 2 | 2011 | 1632 | 0.100 |
Why?
|
| ROC Curve | 2 | 2015 | 3532 | 0.100 |
Why?
|
| Heart Septal Defects, Atrial | 2 | 1995 | 468 | 0.100 |
Why?
|
| Myocardial Infarction | 5 | 2009 | 11842 | 0.100 |
Why?
|
| Dogs | 2 | 2016 | 3840 | 0.100 |
Why?
|
| Double-Blind Method | 10 | 2019 | 12328 | 0.100 |
Why?
|
| Prospective Studies | 12 | 2024 | 53809 | 0.100 |
Why?
|
| Aspirin | 6 | 2004 | 3341 | 0.100 |
Why?
|
| Liver Transplantation | 3 | 1998 | 2236 | 0.090 |
Why?
|
| Cyclophosphamide | 1 | 1997 | 2194 | 0.090 |
Why?
|
| Organ Specificity | 2 | 2014 | 1952 | 0.090 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2013 | 686 | 0.090 |
Why?
|
| Alleles | 2 | 2020 | 6879 | 0.090 |
Why?
|
| Severity of Illness Index | 6 | 2020 | 15680 | 0.090 |
Why?
|
| Longitudinal Studies | 5 | 2014 | 14325 | 0.090 |
Why?
|
| Ventricular Dysfunction | 2 | 2001 | 145 | 0.090 |
Why?
|
| Myocardial Ischemia | 1 | 2001 | 2155 | 0.090 |
Why?
|
| Evidence-Based Medicine | 4 | 2021 | 3678 | 0.090 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 1991 | 271 | 0.090 |
Why?
|
| Immunoglobulin G | 2 | 2020 | 4518 | 0.090 |
Why?
|
| Protein Multimerization | 1 | 2015 | 970 | 0.090 |
Why?
|
| Heart Valve Prosthesis | 3 | 2010 | 1500 | 0.090 |
Why?
|
| Quality of Life | 4 | 2006 | 13154 | 0.090 |
Why?
|
| Thrombosis | 2 | 1995 | 3018 | 0.090 |
Why?
|
| Biological Transport | 1 | 2014 | 2073 | 0.080 |
Why?
|
| Recurrence | 6 | 2015 | 8420 | 0.080 |
Why?
|
| Follow-Up Studies | 11 | 2015 | 39077 | 0.080 |
Why?
|
| Norepinephrine | 1 | 1992 | 898 | 0.080 |
Why?
|
| Lysosomes | 1 | 2014 | 911 | 0.080 |
Why?
|
| Antibodies | 1 | 2017 | 2412 | 0.080 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2011 | 1515 | 0.080 |
Why?
|
| Tinnitus | 1 | 2011 | 190 | 0.080 |
Why?
|
| Multivariate Analysis | 3 | 2014 | 12138 | 0.080 |
Why?
|
| Pyrazoles | 1 | 2019 | 1984 | 0.080 |
Why?
|
| Epinephrine | 1 | 1992 | 788 | 0.080 |
Why?
|
| Atropine | 2 | 1986 | 240 | 0.080 |
Why?
|
| Hidradenitis Suppurativa | 1 | 2012 | 174 | 0.080 |
Why?
|
| Atherosclerosis | 1 | 2024 | 3503 | 0.080 |
Why?
|
| Europe | 3 | 2020 | 3396 | 0.080 |
Why?
|
| Models, Theoretical | 1 | 2020 | 3546 | 0.080 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 6 | 2004 | 5551 | 0.080 |
Why?
|
| Peer Review | 1 | 1990 | 218 | 0.070 |
Why?
|
| Plaque, Amyloid | 1 | 2012 | 747 | 0.070 |
Why?
|
| Pilot Projects | 3 | 2023 | 8443 | 0.070 |
Why?
|
| Delphi Technique | 2 | 2021 | 798 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2006 | 10196 | 0.070 |
Why?
|
| Boronic Acids | 1 | 2011 | 907 | 0.070 |
Why?
|
| Pulmonary Circulation | 1 | 2010 | 742 | 0.070 |
Why?
|
| Carotid Sinus | 1 | 1986 | 44 | 0.070 |
Why?
|
| Capsules | 1 | 1987 | 193 | 0.070 |
Why?
|
| Propranolol | 1 | 1988 | 489 | 0.070 |
Why?
|
| Heart Massage | 1 | 1986 | 30 | 0.070 |
Why?
|
| Amyloid Neuropathies | 2 | 1998 | 15 | 0.070 |
Why?
|
| Autophagy | 1 | 2014 | 1324 | 0.070 |
Why?
|
| Alopecia | 1 | 2011 | 413 | 0.070 |
Why?
|
| Myocytes, Cardiac | 2 | 2013 | 1631 | 0.070 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2020 | 8933 | 0.070 |
Why?
|
| Nuclear Medicine | 2 | 2019 | 234 | 0.070 |
Why?
|
| Mitral Valve | 3 | 2010 | 1475 | 0.070 |
Why?
|
| Atrioventricular Node | 1 | 1986 | 180 | 0.070 |
Why?
|
| Glycoproteins | 1 | 2013 | 2195 | 0.060 |
Why?
|
| Retrospective Studies | 6 | 2022 | 79133 | 0.060 |
Why?
|
| Remission Induction | 4 | 2019 | 2368 | 0.060 |
Why?
|
| Pyrazines | 1 | 2011 | 1192 | 0.060 |
Why?
|
| Apoptosis | 2 | 2013 | 9429 | 0.060 |
Why?
|
| Blood Proteins | 1 | 2011 | 1155 | 0.060 |
Why?
|
| Observer Variation | 2 | 2010 | 2583 | 0.060 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2011 | 1002 | 0.060 |
Why?
|
| Exercise Test | 4 | 1997 | 2118 | 0.060 |
Why?
|
| Epidemiologic Methods | 1 | 2010 | 1340 | 0.060 |
Why?
|
| Quinidine | 1 | 1984 | 54 | 0.060 |
Why?
|
| Benzeneacetamides | 1 | 1984 | 36 | 0.060 |
Why?
|
| Cardiac Resynchronization Therapy | 1 | 2011 | 552 | 0.060 |
Why?
|
| Extracellular Matrix | 1 | 2012 | 1717 | 0.060 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2017 | 3327 | 0.060 |
Why?
|
| Inflammation | 1 | 2024 | 10696 | 0.060 |
Why?
|
| Scoliosis | 1 | 2011 | 724 | 0.060 |
Why?
|
| Infusions, Intravenous | 5 | 2019 | 2221 | 0.060 |
Why?
|
| Dexamethasone | 1 | 2011 | 1925 | 0.060 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2011 | 1422 | 0.060 |
Why?
|
| Incidence | 3 | 2019 | 21157 | 0.060 |
Why?
|
| Sensitivity and Specificity | 4 | 2005 | 14588 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2015 | 6501 | 0.060 |
Why?
|
| Hemodynamics | 4 | 2001 | 4173 | 0.060 |
Why?
|
| Linear Models | 2 | 2012 | 5859 | 0.060 |
Why?
|
| Cardiovascular Agents | 1 | 2010 | 866 | 0.050 |
Why?
|
| Inhalation Exposure | 1 | 2006 | 429 | 0.050 |
Why?
|
| California | 1 | 2007 | 1396 | 0.050 |
Why?
|
| Phenotype | 2 | 2020 | 16443 | 0.050 |
Why?
|
| Nerve Fibers, Unmyelinated | 1 | 2003 | 97 | 0.050 |
Why?
|
| Risk Assessment | 4 | 2024 | 23788 | 0.050 |
Why?
|
| Nutrition Disorders | 1 | 1983 | 206 | 0.050 |
Why?
|
| Age Factors | 4 | 2019 | 18298 | 0.050 |
Why?
|
| Carbon | 1 | 2006 | 670 | 0.050 |
Why?
|
| Molecular Imaging | 2 | 2019 | 826 | 0.050 |
Why?
|
| Diltiazem | 1 | 2002 | 131 | 0.050 |
Why?
|
| Nephrotic Syndrome | 3 | 2001 | 389 | 0.050 |
Why?
|
| Random Allocation | 4 | 1988 | 2387 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2004 | 10796 | 0.050 |
Why?
|
| Cardiac Tamponade | 1 | 1983 | 171 | 0.050 |
Why?
|
| Proportional Hazards Models | 2 | 2010 | 12455 | 0.050 |
Why?
|
| Pleura | 1 | 2003 | 243 | 0.050 |
Why?
|
| Particle Size | 1 | 2006 | 1633 | 0.050 |
Why?
|
| Animals | 9 | 2017 | 166811 | 0.050 |
Why?
|
| Lymphangiomyoma | 1 | 2001 | 9 | 0.050 |
Why?
|
| Alkylating Agents | 1 | 2001 | 133 | 0.050 |
Why?
|
| Evaluation Studies as Topic | 3 | 1991 | 1634 | 0.050 |
Why?
|
| Medicare | 1 | 2019 | 6686 | 0.050 |
Why?
|
| Food-Drug Interactions | 1 | 2000 | 25 | 0.050 |
Why?
|
| Blood Pressure | 3 | 2004 | 8465 | 0.050 |
Why?
|
| Referral and Consultation | 2 | 2011 | 3562 | 0.050 |
Why?
|
| Pre-Excitation Syndromes | 1 | 2000 | 27 | 0.050 |
Why?
|
| Organotechnetium Compounds | 1 | 2020 | 134 | 0.040 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2020 | 70 | 0.040 |
Why?
|
| Heterozygote | 2 | 2015 | 2785 | 0.040 |
Why?
|
| Cause of Death | 3 | 2020 | 3685 | 0.040 |
Why?
|
| Sensory Thresholds | 2 | 1993 | 378 | 0.040 |
Why?
|
| Cohort Studies | 6 | 2023 | 40980 | 0.040 |
Why?
|
| Technetium Tc 99m Medronate | 2 | 2018 | 133 | 0.040 |
Why?
|
| Cerebral Amyloid Angiopathy | 1 | 2007 | 879 | 0.040 |
Why?
|
| Exercise | 2 | 1997 | 5746 | 0.040 |
Why?
|
| Heart Arrest | 2 | 1986 | 1480 | 0.040 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 1999 | 620 | 0.040 |
Why?
|
| Prednisone | 3 | 2004 | 1563 | 0.040 |
Why?
|
| Electroencephalography | 1 | 2014 | 6047 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2020 | 17647 | 0.040 |
Why?
|
| Fatal Outcome | 2 | 2010 | 1828 | 0.040 |
Why?
|
| Finland | 1 | 2019 | 593 | 0.040 |
Why?
|
| Knowledge | 1 | 2020 | 175 | 0.040 |
Why?
|
| Macroglossia | 1 | 1998 | 12 | 0.040 |
Why?
|
| Coronary Care Units | 1 | 1979 | 231 | 0.040 |
Why?
|
| Parotid Gland | 1 | 2019 | 174 | 0.040 |
Why?
|
| Ecchymosis | 1 | 1998 | 32 | 0.040 |
Why?
|
| Zebrafish | 3 | 2014 | 2995 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2019 | 20351 | 0.040 |
Why?
|
| Stress, Mechanical | 1 | 2003 | 1661 | 0.040 |
Why?
|
| Immunohistochemistry | 3 | 2013 | 11008 | 0.040 |
Why?
|
| Therapeutic Equivalency | 1 | 1998 | 136 | 0.040 |
Why?
|
| Death Certificates | 1 | 2018 | 167 | 0.040 |
Why?
|
| Polyneuropathies | 1 | 2019 | 136 | 0.040 |
Why?
|
| Combined Modality Therapy | 4 | 2002 | 8539 | 0.040 |
Why?
|
| Reference Values | 2 | 2017 | 4898 | 0.040 |
Why?
|
| Syncope, Vasovagal | 1 | 1997 | 38 | 0.040 |
Why?
|
| Hemolysis | 1 | 1979 | 423 | 0.040 |
Why?
|
| Patient Selection | 3 | 2001 | 4239 | 0.040 |
Why?
|
| Valine | 1 | 1999 | 408 | 0.040 |
Why?
|
| Biological Availability | 1 | 1998 | 396 | 0.040 |
Why?
|
| Hypertrophy, Right Ventricular | 1 | 1997 | 108 | 0.040 |
Why?
|
| Prednisolone | 1 | 1998 | 324 | 0.040 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 1998 | 276 | 0.030 |
Why?
|
| Phonocardiography | 1 | 1996 | 30 | 0.030 |
Why?
|
| Psychoses, Substance-Induced | 1 | 1977 | 95 | 0.030 |
Why?
|
| Alanine | 1 | 1999 | 584 | 0.030 |
Why?
|
| Isoelectric Focusing | 3 | 2002 | 160 | 0.030 |
Why?
|
| Public Opinion | 1 | 2020 | 480 | 0.030 |
Why?
|
| Piperidines | 1 | 1984 | 1645 | 0.030 |
Why?
|
| Lung Diseases | 1 | 2006 | 1899 | 0.030 |
Why?
|
| DNA | 1 | 2009 | 7215 | 0.030 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1999 | 882 | 0.030 |
Why?
|
| North America | 1 | 2019 | 1279 | 0.030 |
Why?
|
| Delayed Diagnosis | 1 | 2019 | 452 | 0.030 |
Why?
|
| Hypertension | 2 | 2007 | 8498 | 0.030 |
Why?
|
| Exercise Tolerance | 1 | 2020 | 808 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2019 | 2285 | 0.030 |
Why?
|
| Rheumatic Heart Disease | 2 | 2010 | 165 | 0.030 |
Why?
|
| Canada | 1 | 2020 | 2104 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 7400 | 0.030 |
Why?
|
| Autoradiography | 1 | 2015 | 737 | 0.030 |
Why?
|
| Membrane Potentials | 1 | 1997 | 1096 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 1987 | 3203 | 0.030 |
Why?
|
| Gout Suppressants | 1 | 1996 | 171 | 0.030 |
Why?
|
| Stress, Physiological | 2 | 1997 | 1392 | 0.030 |
Why?
|
| Dilatation, Pathologic | 1 | 1995 | 518 | 0.030 |
Why?
|
| Fee-for-Service Plans | 1 | 2019 | 697 | 0.030 |
Why?
|
| Anemia, Sickle Cell | 1 | 1982 | 1055 | 0.030 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2018 | 1067 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 1987 | 3821 | 0.030 |
Why?
|
| Transplantation, Autologous | 3 | 2004 | 2109 | 0.030 |
Why?
|
| Thumb | 1 | 1995 | 228 | 0.030 |
Why?
|
| Oscillometry | 1 | 1993 | 144 | 0.030 |
Why?
|
| Edema | 2 | 2010 | 770 | 0.030 |
Why?
|
| Cerebral Hemorrhage | 1 | 2004 | 2645 | 0.030 |
Why?
|
| Comorbidity | 1 | 2007 | 10475 | 0.030 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 1 | 2015 | 487 | 0.030 |
Why?
|
| Drugs, Generic | 1 | 1998 | 446 | 0.030 |
Why?
|
| Cardiac Output, Low | 1 | 1993 | 192 | 0.030 |
Why?
|
| Age Distribution | 1 | 2018 | 2884 | 0.030 |
Why?
|